Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws.
On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth." Culper Research's short report contends ASCENIV only achieved its growth on the back of "classic channel stuffing." ADMA's annual report further claimed its commercial execution was "expected to accelerate demand utilization while maintaining cost discipline." Yet, Culper contends that members of ADMA's distributor attested that "underlying demand 'is not really growing.'"
The gap between the reported 20% revenue growth and the alleged 3% decline represents a substantial divergence. ADMA stock dropped sharply immediately following publication of the short-seller report on March 24, 2026 and throughout the following days.
If you suffered a loss on your ADMA Biologics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290218
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims
2026-03-27 11:50 AM EDT
Fraud Investigation Opened: Levi & Korsinsky Investigates Freshpet, Inc. (FRPT) on Behalf of Shareholders
2026-03-25 9:47 AM EDT
Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS) - Contact Levi & Korsinsky to Protect Your Rights
2026-03-23 12:15 AM EDT
Jan 30, 2026
To understand where public relations and investor communications are headed, we analyzed over 39,000 press releases distributed in 2025. The data is clear: success now depends on a careful balance between AI-readability and human trust. More than 50% of news activity on the TMX Newsfile network is now driven by AI bots from OpenAI and Microsoft. Yet these systems rely on human-verified facts to ground their answers. We have entered a “ zero-click ” reality, where Generative AI systems...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services